ACM
CMPX icon

ADAR1 Capital Management’s Compass Therapeutics CMPX Stock Holding History

ADAR1 Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267K Sell
122,132
-16,868
-12% -$49.8K 0.01% 240
2026
Q1 		$735K Hold
139,000
– – 0.04% 183
2025
Q4 		$746K Buy
139,000
+89,000
+178% +$411K 0.05% 157
2025
Q3 		$175K Buy
50,000
+25,000
+100% +$79K 0.02% 183
2025
Q2 		$65K Buy
+25,000
New +$51.6K 0.01% 186
2024
Q2 		– Sell
-10,206
Closed -$20.2K – 282
2024
Q1 		$20.2K Buy
+10,206
New +$17.6K ﹤0.01% 216

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ADAR1 Capital Management's CMPX Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Compass Therapeutics (CMPX) stake by 12% in Q2 2026, selling an estimated $49.8K and leaving 122,132 shares worth $267K. The position accounts for 0.01% of the portfolio, ranked #240.

ADAR1 Capital Management first reported a position in CMPX in Q1 2024 and has held it in 6 quarters since. The position peaked at $746K in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • ADAR1 Capital Management held 122,132 shares of Compass Therapeutics worth $267K as of Q2 2026.
  • ADAR1 Capital Management sold 16,868 Compass Therapeutics shares in Q2 2026, an estimated $49.8K.
  • Compass Therapeutics made up 0.01% of ADAR1 Capital Management's portfolio in Q2 2026, its #240 holding.
  • ADAR1 Capital Management first reported a position in Compass Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • ADAR1 Capital Management's Compass Therapeutics position peaked at $746K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.